Sage Therapeutics
There have been three new appointments at neuroscience-focused Sage Therapeutics.
Dr. Jeffrey Jonas (main) has been named CEO and will succeed interim CEO, Kevin Starr. Jonas has over 20 years of experience in the industry and was most recently the President of Regenerative Medicine at Shire.
Dr. Stephen Kanes (inset) - previously Executive Director/Therapeutic Area Clinical Director for the Inflammation, Neuroscience and Respiratory GMED division of AstraZeneca – has been named Chief medical Officer.
Kimi Iguchi, not pictured, will serve as Chief Financial Officer and comes to Sage from Santhera Pharmaceuticals.
Dr. Steven Paul, Sage’s co-founder, said: “These additions add to our already excellent R&D team, validating the work that SAGE has done to date to build a highly productive drug discovery platform that could yield multiple new medicines over the next few years.”